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ABSTRACT 
 
 
 Five to ten percent of HIV-1 infected individuals remain asymptomatic up to a 
year after infection.  This type of infection is known as a long-term non-progressive 
(LTNP) infection, and can be characterized as a viral phenotype with a lack of CD4+ T-
cell death.  This MQP deals specifically with a group of LTNPs known as the French 
ALT group who have a form of the virus that is considerably less cytopathic.  Because 
mutations in the Viral Protein R (Vpr) region of the HIV-1 genome have been observed 
to cause similar viral phenotypes, the  ALT patient Vpr alleles were investigated.  Several 
Vpr polymorphisms were identified in hypervariable loci, most of which result in 
significant amino acid changes.  In the future, these mutations will be mimiced in wild-
type HIV’s to determine their effect on viral replication to determine if they are 
responsible for the LTNP phenotype. 

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BACKGROUND 
 
 
HIV:  Introduction  
 
The study of human immunodeficiency virus (HIV) is one of the most relevant 
and exciting research topics today. One of the reasons it is so interesting is because of its 
worldwide impact (see Figure 1).  HIV is a retrovirus first identified in 1983 and is the 
cause of AIDS.  The basic pathology exhibited by individuals infected by this virus is a 
loss of CD4+ lymphocytes, and a variety of immune disorders (Levy 1998).   HIV is 
present today in two classes and many different subtypes, some more prevalent than 
others in specific areas of the world.  HIV-2, the second class of HIV, is closely related to 
SIV and is thought to be an earlier form of the virus (Knipe and Howley, 2001).  
    
 
 
 
 
 
 
 
 
 
Figure 1:  HIV Subtype Distribution.  This figure shows the distribution of HIV 
throughout the world as of 1996 (Levy, 1998). 
 
 
 
The disease caused by the HIV virus is characterized by immunological 
abnormalities, opportunistic infections, and a weakened immune system. HIV infection 
itself can also cause neurological disorders, and unusual forms of cancer (Knipe and 
Howley, 2001).  The virus is transmitted through fluid transfer, either intravenous or 
sexual.  The virus is present at infectious levels in the blood and genital fluids of infected 
individuals (Jaffe et al, 1983).  HIV-1 is a typical lentivirus, and may have evolved from 
a similar simian immunodeficiency virus (SIV) found in monkeys and non-human 
primates (Knipe and Howley, 2001).  Genetically SIV (especially from Sooty 
Mangabeys) and HIV-2 are very similar.  This suggests that the HIV-2 may be an older 
form of the virus.  It is hypothesized that HIV developed first in non-human primates, 
and then switched over to the human population at some time.  The HIV virion contains 
two identical copies of a single stranded RNA genome; each is about 9.2 thousand base 
pairs long.   
 
HIV-1 Genome 
Like any lentivirus, HIV has the structural genes Gag, Pol, and Env. These genes 
encode the proteins that make up the majority of the mature virion.  HIV also has a set of 
regulatory genes, Tat and Rev, (see Figure 2) which control the expression of viral 
proteins once integration of viral DNA occurs (Levy, 1998).   In addition to these 
regulatory genes HIV also has a set of accessory genes.  These genes encode proteins that 
have evolved to facilitate the virus in its infection, and eradicate or control cellular 
cofactors poised to inhibit viral activity.  The accessory genes are Nef, Vif, Vpu, Vpx, 
and Vpr (Knipe and Howley, 2001). 
 
 
 
 
Figure 2:  Diagram of the HIV Genome and Virion Structure.  Part A shows 
the position of various genes in the HIV genome.  Part B shows a diagram of the 
mature HIV virion.  Most HIV genes are arranged in this basic pattern with only 
slight differences in position due to differences in subtype, or mutation.  Taken 
from (Knipe and Howley, 2001). 
 
 
Viral Entry and Replication 
Viral entry occurs predominantly through the conformational interaction of 
surface glycoprotein 120 (gp120) and the CD4 cellular receptor (Capon and Ward, 1991).  
After gp120 has come into contact with a CD4 receptor, the gp120 is displaced which 


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allows the hydrophobic viral gp41 to come into contact with the cell and aid fusion 
(Moore et al, 1991) (see Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: HIV-1 Fusion Model.  This figure shows the role of the HIV-1 surface 
glycoproteins during fusion.  During this stage of infection the viral glycoprotein 
41 undergoes a conformational change to facilitate the fusion of the virion, and 
eventual entrance of the HIV nucleocapsid.   Figure taken from (Knipe and 
Howley, 2001). 
 
In addition to CD4 as a receptor, HIV-1 may also use a co-receptor to facilitate 
viral entry in some cell types (Broder et al, 1993).  Chemokine receptors have been found 
to be important HIV co-receptors.  For example, M-tropic HIV infects macrophages 
using CCR-5 as its secondary receptor (Alkhatib et al, 1996) and T-tropic HIV uses 
CXCR-4 as a co receptor when infecting T-cells (Berson et al, 1996).  Once fusion has 
occurred, the HIV-1 nucleocapsid enters the cell through a mechanism that is not clearly 
understood.  Once inside the cell, the single-stranded viral RNA is removed from the 
nucleocapsid and converted to double-stranded, linear DNA by reverse transcriptase 
 	
(Figure 4).  Reverse transcriptase is prone to errors, which gives the HIV genome its high 
mutation rate and high degree of variability.  It is estimated that the RT enzyme 
incorporates the wrong nucleotide during replication once in every 10,000 bases. 
 
Figure 4:  The HIV Infection Cycle.  This figure shows the replication cycle of 
HIV in an infected cell. Once the virus fuses to the cell  (1), it enters and casts aside 
the envelope (2) and then the nucleucapsid. (3).  Then it begins to reverse transcribe 
its single stranded RNA genome (4).  Then a circular provirus is made, transported, 
and incorporated into the chromatin (5).  Once viral DNA is incorporated into host 
cell DNA, replication of HIV viral proteins and genomic RNA is mediated by tat, 
rev, and nef (6). Complete virions are assembled (8) and can be budded off at the cell 
surface (9).  Figure taken from Levy, 1998. 
 
Once this circular non-covalently bonded viral cDNA copy has been made, it is 
transported to the nucleus where it is integrated into the chromosomal DNA.  Once the 
provirus is integrated into the host cell’s chromosomal DNA, the production of viral 
mRNA and genomic RNA is mediated by the relative expression of HIV regulatory genes 
tat, rev, and nef  (Knipe and Howley, 2001). 
A high expression of Tat, and subsequently high levels of the tat-induced gene 
products, yields a large amount of viral production.  High expression of nef may force the 
virus into a latent state (Luciw et al, 1987).  Viral proteins are made from mRNA, and 
copies of genomic viral RNA are formed, and incorporated into capsids. After they are 
 

synthesized, the Gag and Pol proteins of budding virus undergo proteolytic cleavage 
before packaged into the virion. Once complete, virions can either bud off of the infected 
cells surface, or wait inside the cell until the outer membrane is collapsed by apoptosis.  
The virus can also be transmitted directly from cell to cell inside the body.  This method 
of infection is 100 times more efficient than infection by free virus particles (Sato et al 
1992).   
 
HIV Tropisim 
Once inside the body, the virus replicates easily in CD4+ lymphocytes and 
peripheral blood macrophages.  At this point, the virus is considered M-tropic and its 
main entry is via CD4 and CCR-5, this form of the virus is non-syncytia inducing (NSI).  
Syncytia are multinucleated cells formed by cell-to-cell fusion during HIV-1 infection 
(Collman, 1990).  At some point in the infection the virus switches its co-receptor usage 
to CD4 and CXCR-4, and displays a T-tropic behavior where it readily infects and 
destroys T-cells, which is responsible for the accelerated T-cell apoptosis and 
immunodeficiency found in HIV-1 infected individuals.  This T-tropic type of HIV is 
usually found later in infection and is syncytium inducing (SI).   
At this point, opportunistic infection can be observed due to the lack of an active 
T-cell response.  Once the virus destroys the immunological ability of the infected 
individual, they are subjected to severe complications from infections that would have 
been eradicated by a healthy immune system.  Fatalities from advanced HIV are often 
caused by common viruses and infections like pneumonia and influenza. The virus itself 
can also cause cancer, dementia and neurological disorders in its later stages. 
 


 
 
Vpr Background 
 
Structure 
This MQP focused on HIV-1 viral protein R (Vpr), which is a 96 amino-acid 14-
kDa auxiliary regulatory protein present in HIV-1, HIV-2 and SIV.  Vpr is formed from a 
singly spliced mRNA, and can be split into three separate parts:  the amino terminal, the 
carboxyl terminal, and the central alpha-helical structures (Figure 5).  
 
 
 
 
 
 
 
Figure 5:  Structure of the Regulatory Protein Vpr.  This figure shows the 
proposed crystal structure for the Vpr gene product.  Picture Taken from the 
Protein Data Bank Structure Explorer #1ESX. 
 
Mutations in the Vpr amino terminal affect the virus’s ability to package the 
virion effectively, whereas mutations in the carboxyl terminal affect the virus’s ability to 
augment and control the cell cycle.  Finally, mutations in the alpha-helical structures 
influence the virus’s ability to control transcriptional activation, apoptosis, and cellular 
shuttling (Kino and Pavlakis, 2004). 
 
 



 

 
Vpr Function 
 Vpr is not needed for viral replication, but is required for regulation of apoptosis 
and the infection in some non-dividing cell types (Jian and Zhao, 2003).    The Vpr gene 
product is packaged in high copy into the virion and has been shown to play a roll in the 
active nuclear translocation of the HIV-1 pre-integration complex (Lucia et al, 2000).  
This is important because the Vpr gene product can also transport the pre-integration 
complex inside the nucleus of non-dividing cells. Infection of non-dividing cells allows 
HIV to enter more cell types inside the body such as highly specialized cells, as well as 
brain cells. This suggests that an intact Vpr gene is needed to give the virus the ability to 
infect and destroy T-cells, as well as macrophages (Velpandi et al, 2002).  It can also be 
said that an intact Vpr gene is needed for the virus to regulate apoptosis (Samosundaran 
et al, 2002). 
 
In general, apoptosis is the regulated mechanism of controlled cell death, which is 
essential for the normal development and homeostasis of multi-cellular organisms.  The 
cell can undergo apoptosis when stressed or damaged. This destruction of defective cells 
provides a defense against viral infection and oncogenesis (Lucia et al, 2000).  When a 
cell undergoes apoptosis, a calcium dependent endogenous nuclease fragments cellular 
DNA into small nucleotide units. After this occurs, the cell undergoes a convolution of 
the cellular surface, and forms protuberances that pinch off into apoptotic bodies (see 
Figure 6). 
 
 

 
 
 
 
 
 
 
 
Figure 6: Apoptosis Model.  This figure shows a normal cell undergoing apoptosis.  
During apoptosis the cell compacts and segregates its chromatin, followed by convolution 
of the nuclear and cellular envelops. Once the cellular envelope becomes deformed, it 
pinches off into smaller round bodies that can be ingested by macrophages. Figure taken 
from (Levy, 1998, pp 129). 
 
These apoptotic bodies can either float freely, or be eventually consumed by  
macrophage cells.   Early in infection apoptosis can be delayed so as to give the virus 
more time to replicate and assemble virions, before the cell is burst and the virions are 
released.  However later in infection it is important to induce apoptosis to burst the cell 
and release more active virus to try and infect other cells (Razvi and Welsh, 1993).  
Exactly how the virus controls apoptosis is not clearly known, however it is known that 
during HIV-1 infection there is a large increase in apoptosis of immune cells (B and T 
lymphocytes) (Gougeon et al, 1996).  It is this phenomenon that is responsible for the 
CD4+ T-cell loss that causes disease and opportunistic infection in HIV patients.  
Apoptosis can even be induced by soluble viral proteins.  These proteins can either be 
from viral gene expression inside an infected cell, or viral proteins outside the cell can be 
taken inside, and eventually force the cell into apoptosis. Thus, it can be said that 
 
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apoptosis is an important cellular function for HIV to mediate as the infection progresses 
(Lum et al, 2003) . 
 
Vpr Mutations 
Specific mutations in Vpr have been categorized from patient isolates.  Mutations 
in Vpr have been known to alter phenotype in a distinct way.  Specifically mutations in 
the alpha helical regions of the gene product impact the virus negatively, impairing its 
ability to induce apoptosis and mediate infection.  This mutated form of the virus is 
unable to deplete T-cells unlike wild type (see Figure 7) (Somasundaran et al, 2002).   
 
 
Figure 7:  Cytopathicity of Wildtype LAI Strains Versus Mutated Patient Vpr 
Alleles.   This figure shows the number of viable cell vs. time after infection for 
various HIV isolates.  Vpr’s  I-IV are mutated non functional Vpr alleles inserted into 
wildtype LAI virus.  The virus with these inactive non-coding Vpr alleles can not 
decrease the amount of viable cells; these viruses cannot efficiently cause infected 
cells to undergo apoptosis as does wildtype virus (clear diamonds).  Figure from 
(Somasundaran et al, 2002). 
 
 
 
This lack of CD4+ T-cell destruction in Vpr mutants confers a specific viral 
phenotype to patients infected with this form of the virus.  Since the virus does not 
deplete their T-cells as quickly, they are known as long term non-progressors (LTNP).  
 
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Individuals infected with a form of the virus that cannot efficiently kill T-cells do 
not get as much damage to their immune system.  Typically these patients live longer.  
Another example of a severe Vpr mutation is the Q3R mutation, which occurs at the N-
terminus of Vpr.  This mutation affects the cytopathic and apoptotic ability of the virus.  
The Q3R substitution occurs at the third amino acid in the gene product, where a 
Glutamine is switched to an Arginine.  The Q3R form of the virus is not very cytopathic 
when compared to a non-mutated virus (see Figure 8).  
 
Figure 8: Replication of wt LAI versus Q3R.  The wt LAI virus (dark circles) 
has a larger decrease in viable cell count when compared to LAI with the Q3R 
polymorphisim (open boxes).  LAI Q3R also produces higher levels of p24 
than wild type LAI.  This suggests that there is more replication and less 
apoptosis occurring with the Q3R virus.   This figure is from (Somasundaran et 
al, 2002). 
 
Cytopathicity describes the virus’s ability to induce cell death and apoptosis.  This 
lack of cell death found in the Q3R form of the virus suggests that a functional Vpr is 
needed for the virus to be cytopathic (Somasundaran et al, 2002).  This lack of 
cytopathicity and apoptosis shows that the Q3R mutation reduces the virus’s ability to 
induce apoptosis, because this polymorphism harms the Vpr gene product, which plays a 
role in controlling apoptosis and cell death.  
 
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From studying the differences in phenotype between Vpr-negative viruses and 
wild type viruses, it has been found that Vpr plays a role in the nuclear localization of the 
pre-integration complex as well as apoptosis, which is lowered considerably when the 
virus has a non-functional Vpr. This tells us that the Vpr gene product may regulate 
apoptosis (see Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Effect of Vpr Mutations on Apoptotic Index.  This figure shows 
apoptotic ability of truncated, non functional Vpr versus wild type LAI Vpr.  
Vpr-negative virus shows less apoptosis; this suggests that Vpr plays a large role 
in mediating this cellular process (Somasundaran et al, 2002). 
 
 
 
 
 
French ALT Background  
This MQP research is based around the study of an unusual group of HIV patients 
who are infected with the virus but do not exhibit normal viral phenotype.  These patients 
have high viral loads yet also retain high levels of CD4+ T-cells (Candotti et al,  1999). 
Normally patients that have a steady viral load and normal viral replication have low 
 
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levels of CD4+ T lymphocytes, but these patients show high T-cell counts even with 
relatively high viral loads, as shown by Figure 10 below. 
 
 
 
 
 
 Figure 10:  Long Term Asymptomatic HIV-1 Infection.  This figure shows plasma 
RNA load of each of the patients in the French ALT group.  The patients are grouped 
initially by starting viral load (entry listing).  The total amount of HIV plasma RNA 
remains relatively the same even after a year.  This steady level of plasma viremia and 
lack of CD4+ T-cell death allows us to classify these patients as long-term 
asymptomatic individuals.  Filled circles denote patients who had a significant increase 
in viral load, while clear circles denote those who have not increased significantly.  
Figure is from Candotti et al, 1999. 
 
 
 
This form of HIV from the ALT patients exhibits a lack of viral cytopathicity and 
Vpr dependent apoptosis, but it can replicate efficiently and is also able to enter cells, but 
cannot destroy cells through apoptosis.  Viral levels in plasma do not increase 
significantly overtime, probably due to the lack of cell rupture and cytopathicity normally 
associated with wild type HIV.  It is the main focus of this MQP to investigate the Vpr 
alleles of the virus from the French ALT group, looking for polymorphisms.  These 
polymorphisms in Vpr may be responsible for the long term asymptomatic infection, and 
 
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lack of Vpr dependent apoptosis.  This would explain the peculiar phenotype of the virus 
found in the French ALT Study Group.  
The correlation between non functional Vpr and lack of apoptosis suggests that 
the French ALT group of patients, who exhibit low levels of apoptotic activity, may have 
mutations in their Vpr alleles.  This similarity is the cause for the investigation of the 
ALT Vpr alleles.  Specifically polymorphisms that cause truncations or premature stops 
in the gene product, or convert the hydrophobicity of a key aa, can cause the Vpr- 
phenotype.  
Not much is known about the viral accessory proteins and their exact role in 
successful infection.  At this point it is known that a non functional Vpr allele can cause 
the virus to loose the ability to cause apoptosis, but will not stop the virus from 
replicating (Somasundaran et al, 2002).  This resembles the phenotype of the LTNP’s 
(long term non-progressors) discussed above.  However it is not known completely which 
specific sequence polymorphisms in Vpr alleles result in augmented viral phenotypes of 
the ALT patients.  There are certainly new mutations in Vpr that can be shown to confer 
the LTNP status.  This MQP study and sequence analysis of the Vpr alleles will allow us 
to look into certain Vpr mutations and their effect on viral cytopathicity, infectivity, and 
apoptosis.  Hopefully some new mutations can be uncovered in this group of 
asymptomatic HIV-1 patients.  Learning where on the gene mutations occur and how 
these mutations change phenotype will allow us to better understand the role of the Vpr 
gene product during infection.  
 
	
PROJECT PURPOSE 
 
 
The purpose of this MQP is to investigate HIV-1 infection in the French ALT 
Group of long term non-progressors, especially characterizing various Vpr alleles that 
may be responsible for the unusual phenotype.  The phenotype of the virus from these 
patients is very strange since the virus replicates efficiently but does not decrease viable 
T-cell count by inducing cell death the way wild type virus does.  The HIV-1 Viral 
protein R (Vpr) is known to play an important role in nuclear import and apoptosis, so is 
the target protein in this project.   If mutations in the French ALT Vpr are found, then 
future experiments can be performed to test the effects of mimicking these mutations in 
wt isolates on viral replication and apoptosis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
 
Sample Information 
Purified HIV samples were obtained from peripheral blood cells of a French ALT 
Group of long term non-progressors (Somasundaran et al, 2002).  The samples are all 
classified as HIV-1 and they are all subtype B.  Our lab obtained these 33 samples by 
mail from Dr. Candotti (Umass). 
 
Plasmid Vector Selection  
 Once these HIV samples were obtained, a plasmid pIRES2-EGFP vector from 
BD Biosciences ® was selected containing a GFP ORF, as well as a Kanamycin 
resistance gene shown on the vector map (see Figure 11).  
 
 
 
 
 
 
 
Figure 11:  Plasmid Vector Map (pIRES vector map BD Biosciences) 
 
 
 
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The vector also has an internal ribosome binding site to allow protein production.  
The MCS area on Figure 11 depicts the multiple cloning site of the vector which was cut 
out and replaced by the ALT Vpr alleles. The MCS section removed was site 615 to 662. 
When this section was removed, the 96 amino acid Vpr allele amplified from PCR was 
inserted in its place.  
 
Preparation of Vector DNA 
After the pIRES vector was chosen, LB media was inoculated and a large scale 
plasmid DNA preparation was done using the Qiagen Maxi prep protocol, with no major 
changes in the recommended protocol. This vector will carry the VPR allele from each of 
the numbered ALT samples.   
 
 
Construction of Vpr Primers 
Vpr complementary nucleotide sequences were designed using a map of the HIV-
1 genome.  These oligonucleotides were ordered from Integrated DNA Technologies, Inc.  
Oligonucleotides upstream and downstream from the Vpr gene were constructed to serve 
as the template for amplification.    To specifically amplify only Vpr from each patient 
sample, nested PCR was used.  Nested PCR is a simple dual amplification, an initial 
round of amplification is followed by a second round using primers internal to the first 
set.  The primers used for Vpr amplifications are shown in Table 1 below: 
 
 
 
 
Table I:  Primers for Cloning ALT Vpr Alleles 
 
PCR Round Primer Name Primer Sequence 
1 HVPR 3 Forward CAA  TAC  TTG  GCA  CTA  GCA  GCA  TT Position 5057 in HIV LAI 
1 HVPR 2 Reverse TTA   GGC  TGA  CTT  CCT  GGA   TGC  TT Position 5467 
2 VXI1 Forward CTT  TGC  CTC  GAG  TTA  CGA  AAC  TGA  CAG  AGG A,  Position 5107 
2 VBI   Reverse CTT  CCT  GGA  TCC  TTC  CAG  GGC  TCT   AGT CTA G,  Position 5451 
 
  
This table shows the sequence and position of each primer used in the 
Vpr amplifications. These primers were constructed using a complete 
LAI HIV-1 subtype B sequence taken from the Los Alamos database.   
 
 
PCR  
 
Vpr was amplified by PCR by nested PCR.  In this nested PCR there were two 
rounds of amplifications, the first of which consisted of twenty cycles, and used the first 
set of outside primers.  The second round had thirty cycles, and used the second internal 
set of inside primers. These primers included restriction sites for BamHI and XhoI.  
These restriction sites were included so the amplified DNA could be easily cut and 
inserted into the pIRES vector.   Typically 0.25 g of HIV DNA was used as template in 
each reaction.   After the nested set of amplifications, the PCR products were purified 
using a standard Qiagen PCR purification column, eluted in 30 l.  
 
Restriction Digests  
Purified PCR products and pIRES vector were cut with both BamHI and XhoI. 
These Biolabs ® restriction enzymes were selected on the assumption that they would 
exhibit the least amount of non-specific digestion.  After the restriction digestion, plasmid 
 
vector was mixed with each digested Vpr allele, and the mixture was purified again using 
a standard Qiagen PCR purification column, and eluted in 30 l  
 
Ligation  
 After elution from the column, this combined vector and VPR product was 
ligated using Biolabs ® T4 DNA Ligase in 10 l reactions.   The ligation reaction was 
allowed to proceed at room temperature overnight.  
 
Transformation 
To transform the DNA into bacteria cells Invitrogen ® stbl2 competent cells were 
put on ice and combined with 1.5 l of ligation reaction, heat shocked at 42˚C for 30 sec, 
and allowed to recover at 30˚C for an hour. These cells were then plated on Kanamycin 
plates and left to grow overnight at 37˚C. Once the plates had incubated sufficiently, 4 
colonies from each plate were streaked onto new plates and set aside to incubate a 37˚C 
overnight.  
 
Recombinant DNA Preparation 
Once these re-streaked colonies had grown a thick lawn, small scale DNA preps 
were prepared with Qiagen mini prep columns, these preps were eluted in 30 L. 
 
Recombinant Plasmid Screening 
Another BamHI/XhoI digestion was performed to confirm the presence of the 
patient Vpr allele.  After the digest was complete another agarose gel was run, using an 
 
amplified Vpr band as a control.  When positive bands were observed, colonies from that 
plate were taken to inoculate 200 mL of LB culture for a large scale DNA prep.  
 
Large Scale Recombinant DNA Preparation 
After inserts were confirmed, large scale DNA peps, grown 200 mL cultures, 
were performed to obtain enough DNA for sequencing.  For innoculum a full loop of 
bacteria was placed in 200 mL of LB Broth.  In addition to the desired recombinant 
bacteria, 50mg/mL Kanamycin was added to insure only the growth of the desired 
plasmid.  The cultures were allowed to shake overnight at 37˚C. Bacteria were pelleted, 
and plasmid DNA isolated via Qiagen maxipreps as described above.  
 
Sequencing 
Sequencing was done with Big Dye version 3 at the Umass CFAR sequencing 
center.  One microgram of sample DNA was added to primer 5X diluent and enzyme.  
The samples, went through the sequencing program on the thermo-cycler.   Sequencing 
reactions were cleaned up using Qiagen Dye removal columns. Sequencing was done for 
four separate clones of each sample, these sequences were compared with each other to 
rule out Taq-induced mutations during the PCR.    Sequences were interpreted and 
corrected as electropherograms using ABI prism.  Then sequences were translated and 
aligned using Mac Vector.  Only the most concise and accurate sequencing of patient 
samples are represented in the final alignments.  
 
 
 
Construction of Controls  
 Three HIV controls were constructed to compare against the plasmids that were 
constructed with patient Vpr alleles.  These controls were wt LAI virus Vpr, LAI Vpr  
Q3R polymorphism, and a LAI clone with a Vpr-negative phenotype.   Control Vpr’s 
were ligated and inserted into the pIRES vector in the same method described above for 
patient alleles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
The purpose of this project was to sequence the Vpr gene from several HIV 
isolates from the French ALT LTNP group, and to analyze the effect of any mutations on 
the Vpr protein to determine whether any mutation could help explain the LTNP 
phenotype.  Out of approximately 30 patient clones made and sequenced, the best eight 
isolates showing the most reliable and reproducible sequence data are shown in Figure 12 
below.   
 
 
 
 
 
 
 
 
 
Figure 12:  DNA Sequence Alignment of 300 bp of the Vpr Allele from 8 ALT 
Patients and 3 Controls.   These 8 patients had the most clear and concise 
sequencing data, confirmed by sequencing multiple patient clones.  In this base 
alignment there are four colors, each of which represents a different base. The first 
control is LAI HIV, the second is a Vpr mutated virus that does not code for a 
functional Vpr protein, and finally the third control is the Q3R virus discussed 
above.  Polymorphisms can be clearly seen when comparing numbered ALT patient 
lanes to the wild-type LAI patient control (upper reference sequence). 
 
Patient and control Vpr sequences were examined first as electropherogram print 
outs obtained from the Umass CFAR sequencing facility.  These electropherograms were 
edited if necessary (using multiple cloned allele sequences to ensure that any 
polymorphisms shown represent true changes in the ALT samples, not Taq-induced 
mutations) then imported from the original sequence files to text files.  This was done 
with ABI prism.  After they were imported from ABI prism, sequences were then entered 
into Mac vector, aligned, and translated.  
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 The DNA alignment shows some variability between isolates.  For example, 
position 93 for isolate 5002 contains a C instead of a T as in the wild-type LAI reference 
sequence.  Another example of some variability is the change at position 110 for isolates 
5002 and 8009.  In this case a C is substituted instead of an A.  Mutations at the single 
base level may induce real amino acid changes, or they can be silent mutations not 
predicted to alter protein function much.  Even amino acid substitutions can be relatively 
silent, which can occur when relatively un-important amino acid substitutions occur.  
 To determine whether the base substitutions alter amino acid composition, the 
patient Vpr Alleles were analyzed for open reading frames using Mac Vector’s translate 
function, then a second alignment was constructed (Figure 13).  This translated Vpr 
amino acid alignment shows each patient sample translated along with the three controls 
(see Figure 13 below).  
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Figure 13:  Amino Acid Alignment of 8 Patient and 3 Control Vpr Alleles.    
Sequence variability was observed in each patient sample.   The LAI Vpr 
control (third sequence) can be used as a frame of reference when discussing 
certain amino acids changes in the Vpr gene product. Amino acids that are in 
the same types of colored boxes have similar properties.  The Vpr mutated 
sample had a large amount of variability, which would explain its deficient 
gene product and Vpr- phenotype. 
 
Note: White boxes denote non-polar amino acids, blue boxes are for polar amino acids, 
green boxes are specifically for Proline, and red boxes are for acidic amino acids.   The 
orange boxes represent amino acids Tyrosine and Tryptophan, and yellow boxes 
represent Methionine and Cysteine, whereas pink boxes have only Threonine and Serine. 
 
 
A large amount of variability was observed from patient to patient.  Each patient 
had unique polymorphisms; however some regions were “hyper variable”.  To classify 
the types of mutation, Table 2 was constructed to organize the variability found in the 
patients examined. 
 
 Table 2:  HIV-1 Patient Vpr Variability Index 
                                                                                     Drastic Change 
Patient                   AA#                        AA Change                (Yes or No)  
 
060011  3  Q to R  No  
5002  7  D to N  Yes  
8009  15  R to Y  Yes 
5002  15  R to Y  Yes 
  060011  15  R to Y   Yes  
  5002  19  T to A  Yes  
  060011  22  L to P   Yes  
  04064  23  L to S  Yes  
8009  37  I to P   Yes  
5002  37  I to P  Yes  
  060011  37  I to E   Yes  
5002  41  G to S  Yes 
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  060011  41  G to S   Yes 
5002  45  R to Y  Yes 
  060011  45  R to Y   Yes  
5002  46  I to L  No  
060011  48  E to D  No 
  060011  61  I to L   No 
5002  71  I to T  Yes 
  02011  72  H to Y  Yes 
04034  72  H to Y  Yes 
04064  72  H to Y  Yes 
8013  73  F to L   Yes 
060011  73  F to V  Yes 
5002  78  R to Q   No 
  02011  78  R to N   No  
  04034  82  I to M   Yes  
  8009  83  G to S   Yes 
  5002  84  V to I   No 
  06011  84  V to I   No 
  8009  85  T to V  Yes  
  8013  85  T to S   No 
  060011  85  T to I   Yes  
  8009  86  Q to P   Yes 
  060011  87  Q to R  No  
  8009  88  Q to R   No 
  5002  88  Q to R   No  
8009  90  A to W   Yes 
060011  90  A to T  Yes 
  8009  91  R to S   Yes 
  8009  93  G to I   No  
  
 
Table 2: This table shows the AA variability the 8 ALT patient Vpr alleles exhibited in 
the sequencing done for this MQP.  Multiple patients had variability in specific hyper 
variable regions.   It is especially interesting that there is a Q3R mutation found in 
patient 060011, this mutation would definitely affect viral phenotype in a way that is 
remarkable similar to the lack of viral cytopathicity observed in  the French ALT virus.  
 
Note:  A yes in the far right column in the table above denotes a substitution of an 
amino acid with different physical properties, for example a yes would be scored if a 
hydrophobic amino acid was substituted for a hydrophilic amino acid.  This type of 
variability is more likely to change protein function, but may not necessarily impact 
phenotype.   
 
 
To determine whether the ALT Vpr mutations found in this study correlate with 
highly variable Vpr regions found in the Los Alamos HIV database, the sites of the ALT 
patient Vpr mutations were compared to the Vpr gene for HIV-1 subtype B.  Some 
typical sequences were examined from this database; they are represented below in 
Figure 14. 
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Figure 14: Typical HIV-1 Subtype-B Viral Protein R (Vpr) Amino Acid Alignment.  This figure 
shows the partial alignment of 14 typical HIV-1 subtype-B Vpr proteins found in the Los Alamos database. 
The sequences vary slightly from patient to patient, but extensive variability is observed at certain hyper 
variable positions.   The locations with the most variability in this alignment are positions 15, 28, 37, 41, 
72, 78, 85, and 86.    (all Vpr sequences were obtained from Los Alamos). 
  
 
 A comparison of the hyper variable loci from the ALT patients versus the Los 
Alamos isolates is represented by Table 3.  
 
Table 3: Comparison of ALT and Los Alamos Vpr Hypervariable Loci.  
Number of samples       Drastic AA change  
AA#   with mutations            (Yes or NO)  
  15   3   Yes (all 3) 
  28    0   - 
  37   3   Yes (all 3)  
  41   2   Yes (both) 
  72   3   Yes (all 3) 
  78   2   No  (both) 
  85   3   Yes 2 No1 
  86   1   Yes 
 
Table 3: This table shows a comparison of the Vpr hypervariable loci for 
the 8 ALT patients examined in this MQP versus 14 randomly chosen 
Subtype-B isolates from the Los Alamos database.   
 
 
Just to describe some of the hypervariable loci found in the ALT samples some 
statistics are given in Table 4 below.  Each of the ALT hypervariable loci were also 
hypervariable in the majority of the wild-type Los Alamos samples. 
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Table 4:  Vpr Hypervariable Loci. 
Vpr AA Position Percent (of 8) ALT Samples Variable at This Site 
Percent of 14 Wild-Type 
HIV’s Variable at This 
Site 
15 3/8  37.5% 13 / 14  93 % 
37 3/8  37.5% 9 / 14  64 % 
85 3/8  37.5% 14 / 14  100 % 
41 2/8  25% 7/ 14  50 % 
72 2/8  25% 14 / 14  100 % 
78 2/8  25% 11 / 14  79 % 
86 1/8  12.5% 8 / 14  57 % 
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DISCUSSION 
 
 All of the 8 HIV Vpr hypervariable loci identified in this study for the ALT LTNP 
patients were also found to be hypervariable loci in 14 randomly chosen HIV subtype-B 
HIV sequences from the Los Alamos database.  This fact implies that the hypervariable 
regions of the ALT sequences correlate with hypervariable regions of other HIV-1 
subtype B Vpr isolates previously characterized, which suggests that sequencing done in 
this project was reasonably accurate, and the same Vpr loci change frequently.  However 
many of the ALT mutations change the type of AA and so are predicted to affect Vpr 
function more than the wild-type polymorphisms which tend to be silent.  It remains to be 
shown whether the ALT polymorphisms are responsible for the ALT LTNP phenotype. 
 The results shown in a study by (Di Marzio et al, 1995) imply that Vpr dependent 
cycle arrest is largely controlled by the carboxy-terminal domain of the protein. This was 
shown by comparing mutated Vpr genes, and their gene products.  It was found that the 
amino-terminal, alpha-helical region of Vpr was required for nuclear localization and 
packaging into virions.  Patients that have mutations in this region of HIV most likely 
have a deficient form of the virus.  Vpr position 15 was found to be hypervariable in the 
ALT patients; DiMarzio also found mutations at Vpr position 15 to be hypervariable, 
which would possibly affect nuclear localization and packaging.  
 Another example of the effect of mutations in hypervariable  regions of Vpr, is 
shown by a study completed by (Wang et al, 1996).  Mutations found in positions 83-90, 
which encompasses hypervariable regions 85 an 86 identified in this MQP, confer a 
LTNP phenotype.  In a set of 2 patients, a mother-child pair which has survived for > 13 
years, these patients have mutations in this 85-86 Vpr region.  Even though they are HIV 
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positive they maintained stable CD4+ T-cell counts, so this suggests that mutations in 
this region of Vpr can confer the LTNP status. 
Variability was also observed in ALT Vpr areas not considered hypervariable. For 
example, the Q3R mutation occurs in an area that is not considered hypervariable. There 
was also variability at position 84 for 2 out of the 8 samples sequenced (25%).    
Mutations in these areas may also have negatively impacted the ability of the French 
ALT HIV to cause its peculiar LTNP phenotype.  Future experiments would involve 
mimicing these mutations in wild-type HIV’s to determine whether they affect its ability 
to replicate in permissive cell lines.   
Most of these mutations found in the regions listed in Table 2 above were drastic 
amino acid changes, or changes in the category of amino acid.  These types of amino acid 
changes can drastically affect the capabilities of the protein being produced.  Even 
substitutions of amino acids with similar properties can affect Vpr (Somasundaran et al, 
2002), and in turn the viruses’ ability to induce apoptosis.  For example the Q3R 
mutation is substitution of two similar amino acids, yet it heavily alters viral phenotype 
(Somasundaran et al, 2002).  Patient 060011 had this mutation along with several others, 
so would be predicted to also show diminished replication in cell lines.   
The sequencing done here implies that mutations in Vpr may be responsible for 
the French ALT phenotype; however sequence data alone is not sufficient to truly 
determine whether these mutations are responsible for the LTNP status of the French 
ALT study group.  Infectivity and apoptosis experiments using the constructs made in 
this MQP must be done to correlate specific polymorphisms in patient Vpr alleles with 
the virus’s cytopathic ability.    
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